Product information and disease description Place of product in therapy Disease description Burden of Type I allergic reactions including anaphylaxis

Economic burden and healthcare resource utilization

6 evidence topics · 7 sources

Total annual economic burden of food allergy in the United States

“In a 2013 study by Gupta et al, the annual economic cost of food allergy was estimated to be $24.8 billion, roughly $4,184 per year per child.” (opens the source at this quote in a new tab)
“Annual direct medical costs including hospitalizations, clinician visits, and emergency department visits were $4.3 billion.” (opens the source at this quote in a new tab)

Direct medical cost components from national healthcare database analyses

“Among US studies, a retrospective national US government healthcare database analysis of the annual direct costs of food allergy, including PA, over the years 2006 and 2007 estimated that total annual medical costs were $225 million (2007 US dollars), with office visits accounting for just over half of the cost; the rest of the cost was split among ED visits, inpatient and outpatient visits, ambulance transfers, and AAIs.” (opens the source at this quote in a new tab)

Emergency department utilization for food-allergic reactions

“More generally, recent US population-weighted survey data indicate that approximately 1 in 10 convincingly food-allergic individuals report receiving treatment for a food-allergic reaction in the emergency department within the past 12 months.” (opens the source at this quote in a new tab)

“In the United States (US), recent work suggests that it affects up to 8% of children and 10% of adults and is responsible for an emergency room admission every three minutes” (opens the source at this quote in a new tab)

Trends in anaphylaxis emergency department visits and hospitalizations among United States older adults

“In 2006–2014, older adults experienced approximately 1,019,967 AAR-related ED visits; 173,844 AAR-related hospitalizations; 93,795 anaphylaxis-related ED visits; and 72,677 anaphylaxis-related hospitalizations.” (opens the source at this quote in a new tab)
“While AAR-related ED visit and hospitalization rates remained stable (P-trends=0.28 and 0.16, respectively), anaphylaxis-related ED visit and hospitalization rates significantly increased over time (37 visits per 100,000 population in 2006 to 51 in 2014, P-trend<0.001; 13 hospitalizations per 100,000 population in 2006 to 23 in 2014, P-trend<0.001), especially hospitalization rates for drug-related anaphylaxis (47 hospitalizations per 100,000 population in 2006 to 85 in 2014, P-trend<0.001).” (opens the source at this quote in a new tab)

Inpatient severity and resource intensity of anaphylaxis admissions

“The mean length of stay for these hospitalizations was 6.4 days.” (opens the source at this quote in a new tab)
“Of the total hospitalizations for anaphylaxis occurring between 2006–2014 among older adults, 28% of these visits involved intubation/ventilation, 3% involved cardiac arrest, and 5% of these visits resulted in inpatient death.” (opens the source at this quote in a new tab)

Epinephrine auto-injector acquisition cost and cost-effectiveness at prevailing United States prices

“The retail purchase price of autoinjectors is heterogeneous and often expensive even with insurance, in some instances reaching $690 per dual-pack package (2016 dollars), although retail device costs rarely exceeded $100 before 2010.” (opens the source at this quote in a new tab)
“At a market cost of $715 per twin pack, the autoinjector incremental cost-effectiveness ratio was $2 742 697 per quality-adjusted life-year.” (opens the source at this quote in a new tab)
“The value-based price (incremental cost-effectiveness ratio, $100 000 per quality-adjusted life-year) for personal epinephrine based on 10-fold fatality risk difference was $24.” (opens the source at this quote in a new tab)